4//SEC Filing
BSOF Parallel Master Fund L.P. 4
Accession 0000899243-20-029064
CIK 0001689548other
Filed
Oct 21, 8:00 PM ET
Accepted
Oct 22, 6:45 PM ET
Size
35.7 KB
Accession
0000899243-20-029064
Insider Transaction Report
Form 4
Transactions
- Conversion
Common Stock
2020-10-20+164,832→ 7,594,109 total(indirect: See Footnotes) - Conversion
Series C Redeemable Convertible Preferred Stock
2020-10-20−559,208→ 0 total(indirect: See Footnotes)→ Common Stock (261,318 underlying) - Conversion
Series C Redeemable Convertible Preferred Stock
2020-10-20−1,941,748→ 0 total(indirect: See Footnotes)→ Common Stock (907,378 underlying) - Conversion
Common Stock
2020-10-20+261,318→ 7,429,277 total(indirect: See Footnotes) - Conversion
Common Stock
2020-10-20+907,378→ 907,378 total(indirect: See Footnotes) - Conversion
Series A Redeemable Convertible Preferred Stock
2020-10-20−7,375,799→ 0 total(indirect: See Footnotes)→ Common Stock (3,446,711 underlying) - Conversion
Series B Redeemable Convertible Preferred Stock
2020-10-20−5,052,852→ 0 total(indirect: See Footnotes)→ Common Stock (2,361,198 underlying) - Conversion
Common Stock
2020-10-20+3,446,711→ 4,147,645 total(indirect: See Footnotes) - Conversion
Common Stock
2020-10-20+2,361,198→ 6,508,843 total(indirect: See Footnotes) - Conversion
Common Stock
2020-10-20+659,116→ 7,167,959 total(indirect: See Footnotes) - Conversion
Series B-1 Redeemable Convertible Preferred Stock
2020-10-20−1,410,477→ 0 total(indirect: See Footnotes)→ Common Stock (659,116 underlying) - Conversion
Series C-1 Redeemable Convertible Preferred Stock
2020-10-20−352,734→ 0 total(indirect: See Footnotes)→ Common Stock (164,832 underlying)
BSOF Parallel Master Fund L.P.
10% Owner
Transactions
- Conversion
Common Stock
2020-10-20+261,318→ 7,429,277 total(indirect: See Footnotes) - Conversion
Series C-1 Redeemable Convertible Preferred Stock
2020-10-20−352,734→ 0 total(indirect: See Footnotes)→ Common Stock (164,832 underlying) - Conversion
Common Stock
2020-10-20+2,361,198→ 6,508,843 total(indirect: See Footnotes) - Conversion
Common Stock
2020-10-20+907,378→ 907,378 total(indirect: See Footnotes) - Conversion
Common Stock
2020-10-20+164,832→ 7,594,109 total(indirect: See Footnotes) - Conversion
Series B Redeemable Convertible Preferred Stock
2020-10-20−5,052,852→ 0 total(indirect: See Footnotes)→ Common Stock (2,361,198 underlying) - Conversion
Common Stock
2020-10-20+3,446,711→ 4,147,645 total(indirect: See Footnotes) - Conversion
Common Stock
2020-10-20+659,116→ 7,167,959 total(indirect: See Footnotes) - Conversion
Series A Redeemable Convertible Preferred Stock
2020-10-20−7,375,799→ 0 total(indirect: See Footnotes)→ Common Stock (3,446,711 underlying) - Conversion
Series B-1 Redeemable Convertible Preferred Stock
2020-10-20−1,410,477→ 0 total(indirect: See Footnotes)→ Common Stock (659,116 underlying) - Conversion
Series C Redeemable Convertible Preferred Stock
2020-10-20−559,208→ 0 total(indirect: See Footnotes)→ Common Stock (261,318 underlying) - Conversion
Series C Redeemable Convertible Preferred Stock
2020-10-20−1,941,748→ 0 total(indirect: See Footnotes)→ Common Stock (907,378 underlying)
Transactions
- Conversion
Common Stock
2020-10-20+2,361,198→ 6,508,843 total(indirect: See Footnotes) - Conversion
Common Stock
2020-10-20+164,832→ 7,594,109 total(indirect: See Footnotes) - Conversion
Common Stock
2020-10-20+907,378→ 907,378 total(indirect: See Footnotes) - Conversion
Common Stock
2020-10-20+3,446,711→ 4,147,645 total(indirect: See Footnotes) - Conversion
Series C Redeemable Convertible Preferred Stock
2020-10-20−559,208→ 0 total(indirect: See Footnotes)→ Common Stock (261,318 underlying) - Conversion
Common Stock
2020-10-20+659,116→ 7,167,959 total(indirect: See Footnotes) - Conversion
Common Stock
2020-10-20+261,318→ 7,429,277 total(indirect: See Footnotes) - Conversion
Series B Redeemable Convertible Preferred Stock
2020-10-20−5,052,852→ 0 total(indirect: See Footnotes)→ Common Stock (2,361,198 underlying) - Conversion
Series B-1 Redeemable Convertible Preferred Stock
2020-10-20−1,410,477→ 0 total(indirect: See Footnotes)→ Common Stock (659,116 underlying) - Conversion
Series C Redeemable Convertible Preferred Stock
2020-10-20−1,941,748→ 0 total(indirect: See Footnotes)→ Common Stock (907,378 underlying) - Conversion
Series A Redeemable Convertible Preferred Stock
2020-10-20−7,375,799→ 0 total(indirect: See Footnotes)→ Common Stock (3,446,711 underlying) - Conversion
Series C-1 Redeemable Convertible Preferred Stock
2020-10-20−352,734→ 0 total(indirect: See Footnotes)→ Common Stock (164,832 underlying)
Footnotes (7)
- [F1]All series of Preferred Stock of the Issuer automatically converted into common stock of the Issuer on a 1-for-2.14 basis. Each series of Preferred Stock had no expiration date.
- [F2]Reflects securities held directly by Clarus Lifesciences III, L.P. Clarus Ventures III GP, L.P. is the general partner of Clarus Lifesciences III, L.P. Blackstone Clarus III L.L.C. is the general partner of Clarus Ventures III GP, L.P. The sole member of Blackstone Clarus III L.L.C. is Blackstone Holdings II L.P.
- [F3]Reflects securities held directly by BSOF Parallel Master Fund L.P. Blackstone Strategic Opportunity Associates L.L.C. is the general partner of BSOF Parallel Master Fund L.P. Blackstone Holdings II L.P. is the sole member of Blackstone Strategic Opportunity Associates L.L.C. Blackstone Alternative Solutions L.L.C. is the investment manager of BSOF Parallel Master Fund L.P. Blackstone Holdings I L.P. is the sole member of Blackstone Alternative Solutions L.L.C.
- [F4]The general partner of each of Blackstone Holdings I L.P. and Blackstone Holdings II L.P. is Blackstone Holdings I/II GP L.L.C. The sole member of Blackstone Holdings I/II GP L.L.C. is The Blackstone Group Inc. The sole holder of the Class C common stock of The Blackstone Group Inc. is Blackstone Group Management L.L.C. Blackstone Group Management L.L.C. is wholly-owned by Blackstone's senior managing directors and controlled by its founder, Stephen A. Schwarzman.
- [F5]Information with respect to each of the Reporting Persons is given solely by such Reporting Person, and no Reporting Person has responsibility for the accuracy or completeness of information supplied by another Reporting Person.
- [F6]Due to the limitations of the electronic filing system certain Reporting Persons are filing a separate Form 4.
- [F7]Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
Documents
Issuer
Praxis Precision Medicines, Inc.
CIK 0001689548
Entity typeother
Related Parties
1- filerCIK 0001736665
Filing Metadata
- Form type
- 4
- Filed
- Oct 21, 8:00 PM ET
- Accepted
- Oct 22, 6:45 PM ET
- Size
- 35.7 KB